NEW YORK (GenomeWeb News) – Invitrogen and Applied Biosystems announced separately today that their respective shareholders have voted in favor of the firms’ $6.7 billion merger.
 
Both firms said that around 98 percent of their respective shares were cast in favor of the deal, which is expected to close next month. The transaction already has cleared US antitrust hurdles but still requires clearance from European Union regulators.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.